Poseida Therapeutics, Inc. (PSTX)
Largest Insider Buys in Sector
PSTX Stock Price History Chart
PSTX Stock Performance
About Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating …
Insider Activity of Poseida Therapeutics, Inc.
Over the last 12 months, insiders at Poseida Therapeutics, Inc. have bought $0 and sold $0 worth of Poseida Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Poseida Therapeutics, Inc. have bought $10.12M and sold $7.05M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,150,000 shares for transaction amount of $7.53M was made by Malin Life Sciences Holdings Ltd () on 2022‑08‑08.
List of Insider Buy and Sell Transactions, Poseida Therapeutics, Inc.
| 2022-08-08 | 2.15M 2.6659% | $3.50 | $7.53M | +0.14% | ||||
| 2022-08-08 | Executive Chairman | 142,857 0.1771% | $3.50 | $500,000 | +0.14% | |||
| 2022-08-03 | Sale | Executive Chairman | 160,696 0.1723% | $3.69 | $592,808 | -17.29% | ||
| 2022-03-16 | Chief Operating Officer | 3,000 0.0048% | $3.98 | $11,940 | +3.27% | |||
| 2021-12-06 | 10 percent owner | 1,828 0.003% | $6.90 | $12,613 | -43.32% | |||
| 2021-12-02 | 10 percent owner | 4,296 0.0065% | $6.88 | $29,550 | -47.09% | |||
| 2021-12-01 | 10 percent owner | 18,365 0.0295% | $6.85 | $125,806 | -44.07% | |||
| 2021-11-30 | 10 percent owner | 28,592 0.0451% | $6.85 | $195,838 | -45.04% | |||
| 2021-11-29 | 10 percent owner | 11,057 0.0177% | $6.89 | $76,209 | -44.56% | |||
| 2021-11-26 | 10 percent owner | 27,251 0.0433% | $6.81 | $185,492 | -44.23% | |||
| 2021-11-24 | 10 percent owner | 1,054 0.0016% | $6.89 | $7,260 | -46.80% | |||
| 2021-11-23 | 10 percent owner | 14,625 0.0227% | $6.77 | $98,989 | -45.35% | |||
| 2021-11-19 | 10 percent owner | 11,104 0.0174% | $7.44 | $82,650 | -49.74% | |||
| 2021-11-18 | 10 percent owner | 71,312 0.1129% | $7.18 | $511,685 | -47.31% | |||
| 2021-11-17 | 10 percent owner | 280,384 0.4549% | $7.21 | $2.02M | -46.27% | |||
| 2021-11-17 | Chief Operating Officer | 2,000 0.0032% | $7.00 | $14,000 | -46.27% | |||
| 2021-11-16 | 10 percent owner | 27,680 0.0441% | $7.17 | $198,383 | -46.87% | |||
| 2021-11-08 | Sale | Chief Executive Officer | 18,924 0.0324% | $7.09 | $134,171 | -42.30% | ||
| 2021-10-01 | Sale | Chief Executive Officer | 20,029 0.0319% | $7.02 | $140,604 | -43.97% | ||
| 2021-09-20 | Sale | Chief Executive Officer | 20,000 0.0322% | $8.00 | $160,020 | -47.62% |
Insider Historical Profitability
| Malin Life Sciences Holdings Ltd | 11835673 12.1849% | $2.73 | 13 | 0 | <0.0001% | |
| Hirsch David | director | 2714245 2.7943% | $2.73 | 1 | 0 | <0.0001% |
| Ostertag Eric | Executive Chairman | 838824 0.8636% | $2.73 | 1 | 22 | +0.14% |
| Ingalls Kerry D. | Chief Operating Officer | 55000 0.0566% | $2.73 | 2 | 0 | <0.0001% |
| Lloyd Marcea Bland | director | 10000 0.0103% | $2.73 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $46.17M | 14.93 | 14.47M | +0.9% | +$413,755.76 | <0.01 | |
| Hudson Bay Capital Management LP | $19.06M | 6.16 | 5.97M | 0% | +$0 | 0.53 | |
| BlackRock | $15.79M | 5.11 | 4.95M | -1.61% | -$258,718.57 | <0.0001 | |
| Boxer Capital, LLC | $14.28M | 4.62 | 4.47M | New | +$14.28M | 0.29 | |
| Silverarc Capital Management Llc | $11.47M | 3.71 | 3.6M | -2.95% | -$348,676.56 | 0.12 |